About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Estimating Lymphocyte Counts from DNA Methylation

NCT06586307·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Sixth Affiliated Hospital, Sun Yat-sen University

Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Diagnosed with colorectal cancer by colonoscopy pathology and deemed eligible for immunotherapy after assessment.
2. Neoadjuvant immunotherapy regimen includes PD-1 or anti-PD-L1.
3. R0 resection is performed after neoadjuvant immunotherapy.
4. Complete immunotherapy efficacy assessment data and follow-up data are available.
5. The tissue bank stores the required whole blood and tissue samples for the experiment.

You may not be if

1. Concurrent other malignancies.
2. Neoadjuvant immunotherapy not conducted according to the standard protocol.
3. Severe adverse chemotherapy reactions that lead to the discontinuation of immunotherapy midway.
4. Lack of complete neoadjuvant chemotherapy efficacy assessment data or follow-up data.
5. The tissue bank does not store the required whole blood or tissue samples for the experiment.
6. Patients with concurrent other immune system diseases.

The record

StatusCompleted

PhaseNo phase

Taking part49

StartedJan 2023

UpdatedSep 19, 2024

Conditions

Colorectal Cancers Immunotherapy DNA Methylation

Where1

The Sixth Affiliate Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China

Clareo Health | Estimating Lymphocyte Counts from DNA Methylation